A phase ib study of the combination of personalized autologous dendritic cell vaccine, aspirin, and standard of care adjuvant chemotherapy followed by nivolumab for resected pancreatic adenocarcinoma—a proof of antigen discovery feasibility in three patients

HIGHLIGHTS

• who: Michal Bassani-Sternberg and Lana E. Kandalaft from the James Cook University, Australia have published the Article: A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients, in the Journal: (JOURNAL)
• what: This trial has been approved by Swissmedic and the competent Ethics Committee. The authors hereby set the objectives and design of the study , and the authors demonstrate the feasibility of identifying personalized neoantigens in three PDAC . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.